Beef­ing up its CAR-T pipeline, Gilead teams up with Pfiz­er on a lym­phoma com­bo

Pfiz­er $PFE and Gilead $GILD are join­ing hands on a new com­bo pro­gram that will tie the CAR-T star Yescar­ta with an ear­ly-stage drug that has been bounc­ing around the clin­ic for the last few years.

Pfiz­er’s utomilum­ab (PF-05082566) is al­so in com­bo stud­ies with Keytru­da and Ky­owa Hakko Kirin’s an­ti-CCR4 an­ti­body moga­mulizum­ab. It’s a 4-1BB ag­o­nist, which re­searchers be­lieve could prove a key play­er in spurring an amped up T cell at­tack on can­cer cells among pa­tients with large B-cell lym­phoma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.